Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease

BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell h...

Descripción completa

Detalles Bibliográficos
Autores principales: Cronin, Christopher, McLaughlin, Ronan, Lane, Louise, Brett, Francesca M., Jansen, Michael, Bermingham, Niamh, Wyse, Gerald, Grogan, Liam, Morris, Patrick G., O’Reilly, Seamus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813211/
https://www.ncbi.nlm.nih.gov/pubmed/36619621
http://dx.doi.org/10.3389/fmed.2022.1070828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813211/
https://www.ncbi.nlm.nih.gov/pubmed/36619621
http://dx.doi.org/10.3389/fmed.2022.1070828

Ejemplares similares